SAGE Therapeutics (SAGE) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/19/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SpaceX stock target raised at Oppenheimer. Here’s the new 12-month forecast
- Wall St indexes advance with boost from chips, Iran optimism
- Accenture to buy Dragos, runZero and NetRise for $4.175B
Sage Therapeutics Announces Third Quarter 2016 Financial Results and Provides SRSE European Update
November 3, 2016 6:30 AM EDTPositive Scientific Advice From European Medicines Agency on Development of SAGE-547 in SRSE Provides Regulatory Path in E.U.
Ongoing Phase 3 STATUS Trial Expected to be Sufficient to Support a European Marketing Authorization Application for SAGE-547 in SRSE
Eight Clinical Trials Across Pipeline Expected to Generate Top-Line Data in 2017
Moving into Next Strategic Phase - a Multi-Product, Neuropsych Development Portfolio
Conference Call Today at 8:00 AM ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (NASDAQ:... More
